160 related articles for article (PubMed ID: 27750024)
1. Serum Thyroglobulin Doubling Time in Progressive Thyroid Cancer.
Rössing RM; Jentzen W; Nagarajah J; Bockisch A; Görges R
Thyroid; 2016 Dec; 26(12):1712-1718. PubMed ID: 27750024
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy.
Miyauchi A; Kudo T; Miya A; Kobayashi K; Ito Y; Takamura Y; Higashiyama T; Fukushima M; Kihara M; Inoue H; Tomoda C; Yabuta T; Masuoka H
Thyroid; 2011 Jul; 21(7):707-16. PubMed ID: 21649472
[TBL] [Abstract][Full Text] [Related]
3. High-sensitive basal serum thyroglobulin 6-12 months after thyroid ablation is strongly associated with early response to therapy and event-free survival in patients with low-to-intermediate risk differentiated thyroid carcinomas.
Trimboli P; Zilioli V; Imperiali M; Ceriani L; Giovanella L
Eur J Endocrinol; 2017 May; 176(5):497-504. PubMed ID: 28137736
[TBL] [Abstract][Full Text] [Related]
4. Relationship of biochemically persistent disease and thyroglobulin-doubling time to age at surgery in patients with papillary thyroid carcinoma.
Miyauchi A; Kudo T; Kihara M; Higashiyama T; Ito Y; Kobayashi K; Miya A
Endocr J; 2013; 60(4):415-21. PubMed ID: 23182919
[TBL] [Abstract][Full Text] [Related]
5. [Continously increasing sensitivity in thyroid cancer aftercare in the course of three generations of thyroglobulin IMAs].
Görges R; Brandt-Mainz K; Freudenberg L; Frilling A; Grimm W; Bockisch A
Nuklearmedizin; 2003 Aug; 42(4):157-66. PubMed ID: 12937694
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.
Wassermann J; Bernier MO; Spano JP; Lepoutre-Lussey C; Buffet C; Simon JM; Ménégaux F; Tissier F; Leban M; Leenhardt L
Oncologist; 2016 Jan; 21(1):50-8. PubMed ID: 26675742
[TBL] [Abstract][Full Text] [Related]
7. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
8. Additional value of a high sensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid carcinoma.
Groen AH; Klein Hesselink MS; Plukker JT; Sluiter WJ; van der Horst-Schrivers AN; Brouwers AH; Lentjes EG; Muller Kobold AC; Links TP
Clin Endocrinol (Oxf); 2017 Mar; 86(3):419-424. PubMed ID: 27588675
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the value of first thyroglobulin determination in the diagnostics of metastases immediately following differentiated thyroid carcinoma surgery.
Makarewicz J; Adamczewski Z; Rutkowski A; Mikosiński S; Knapska-Kucharska M; Gonerska-Szadkowska A; Oszukowska L; Karwowska A; Lewiński A
Endokrynol Pol; 2006; 57(4):370-3. PubMed ID: 17006838
[TBL] [Abstract][Full Text] [Related]
10. On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma.
Gholamrezanezhad A; Saghari M; Mirpour S; Beiki D; Tarbiat A; Javan S; Abdollahzadeh J
Endokrynol Pol; 2007; 58(2):100-4. PubMed ID: 17578824
[TBL] [Abstract][Full Text] [Related]
11. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.
Malandrino P; Latina A; Marescalco S; Spadaro A; Regalbuto C; Fulco RA; Scollo C; Vigneri R; Pellegriti G
J Clin Endocrinol Metab; 2011 Jun; 96(6):1703-9. PubMed ID: 21450986
[TBL] [Abstract][Full Text] [Related]
12. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.
Spencer CA; LoPresti JS; Fatemi S; Nicoloff JT
Thyroid; 1999 May; 9(5):435-41. PubMed ID: 10365673
[TBL] [Abstract][Full Text] [Related]
13. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation.
Angell TE; Spencer CA; Rubino BD; Nicoloff JT; LoPresti JS
Thyroid; 2014 Jul; 24(7):1127-33. PubMed ID: 24697314
[TBL] [Abstract][Full Text] [Related]
14. High sensitive thyroglobulin assay on thyroxine therapy: can it avoid stimulation test in low and high risk differentiated thyroid carcinoma patients?
Trimboli P; La Torre D; Ceriani L; Condorelli E; Laurenti O; Romanelli F; Ventura C; Signore A; Valabrega S; Giovanella L
Horm Metab Res; 2013 Sep; 45(9):664-8. PubMed ID: 23720229
[TBL] [Abstract][Full Text] [Related]
15. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response.
Vaisman F; Tala H; Grewal R; Tuttle RM
Thyroid; 2011 Dec; 21(12):1317-22. PubMed ID: 22136267
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum thyroglobulin and changes in serum thyroglobulin during TSH suppression independently predict follicular thyroid carcinoma in thyroid nodules with a cytological diagnosis of follicular lesion.
Kim HJ; Mok JO; Kim CH; Kim YJ; Kim SJ; Park HK; Byun DW; Suh K; Yoo MH
Endocr Res; 2017 May; 42(2):154-162. PubMed ID: 27936964
[TBL] [Abstract][Full Text] [Related]
17. Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC).
Spencer CA
J Clin Endocrinol Metab; 2011 Dec; 96(12):3615-27. PubMed ID: 21917876
[TBL] [Abstract][Full Text] [Related]
18. Early stimulated thyroglobulin for response prediction after recombinant human thyrotropin-aided radioiodine therapy.
Park HJ; Min JJ; Bom HS; Kim J; Song HC; Kwon SY
Ann Nucl Med; 2017 Oct; 31(8):616-622. PubMed ID: 28688088
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer.
Lin Y; Li T; Liang J; Li X; Qiu L; Wang S; Chen Y; Kang Z; Li F
Clin Nucl Med; 2011 Dec; 36(12):1102-5. PubMed ID: 22064080
[TBL] [Abstract][Full Text] [Related]
20. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
